BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 30514397)

  • 1. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
    Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
    Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging.
    Pagès M; Pajtler KW; Puget S; Castel D; Boddaert N; Tauziède-Espariat A; Picot S; Debily MA; Kool M; Capper D; Sainte-Rose C; Chrétien F; Pfister SM; Pietsch T; Grill J; Varlet P; Andreiuolo F
    Brain Pathol; 2019 May; 29(3):325-335. PubMed ID: 30325077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions.
    Tauziède-Espariat A; Siegfried A; Nicaise Y; Kergrohen T; Sievers P; Vasiljevic A; Roux A; Dezamis E; Benevello C; Machet MC; Michalak S; Puiseux C; Llamas-Gutierrez F; Leblond P; Bourdeaut F; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Dangouloff-Ros V; Boddaert N; Saffroy R; Hasty L; Wahler E; Pagès M; Andreiuolo F; Lechapt E; Chrétien F; Blauwblomme T; Beccaria K; Pallud J; Puget S; Uro-Coste E; Varlet P;
    Acta Neuropathol Commun; 2021 Aug; 9(1):135. PubMed ID: 34389065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supratentorial ependymoma in childhood: more than just RELA or YAP.
    Zschernack V; Jünger ST; Mynarek M; Rutkowski S; Garre ML; Ebinger M; Neu M; Faber J; Erdlenbruch B; Claviez A; Bielack S; Brozou T; Frühwald MC; Dörner E; Dreschmann V; Stock A; Solymosi L; Hench J; Frank S; Vokuhl C; Waha A; Andreiuolo F; Pietsch T
    Acta Neuropathol; 2021 Mar; 141(3):455-466. PubMed ID: 33481105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma.
    Tomomasa R; Arai Y; Kawabata-Iwakawa R; Fukuoka K; Nakano Y; Hama N; Nakata S; Suzuki N; Ishi Y; Tanaka S; Takahashi JA; Yuba Y; Shiota M; Natsume A; Kurimoto M; Shiba Y; Aoki M; Nabeshima K; Enomoto T; Inoue T; Fujimura J; Kondo A; Yao T; Okura N; Hirose T; Sasaki A; Nishiyama M; Ichimura K; Shibata T; Hirato J; Yokoo H; Nobusawa S
    Brain Pathol; 2021 May; 31(3):e12943. PubMed ID: 33576087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Rajeshwari M; Singh M; Suri V; Sarkar C; Sharma MC
    J Neurooncol; 2018 May; 138(1):29-39. PubMed ID: 29354850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
    Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
    Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of histopathological ependymoma variants.
    Neumann JE; Spohn M; Obrecht D; Mynarek M; Thomas C; Hasselblatt M; Dorostkar MM; Wefers AK; Frank S; Monoranu CM; Koch A; Witt H; Kool M; Pajtler KW; Rutkowski S; Glatzel M; Schüller U
    Acta Neuropathol; 2020 Feb; 139(2):305-318. PubMed ID: 31679042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology.
    Gessi M; Giagnacovo M; Modena P; Elefante G; Gianno F; Buttarelli FR; Arcella A; Donofrio V; Diomedi Camassei F; Nozza P; Morra I; Massimino M; Pollo B; Giangaspero F; Antonelli M
    Am J Surg Pathol; 2019 Jan; 43(1):56-63. PubMed ID: 29266023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
    Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
    Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review.
    de Sousa GR; Marie SKN; Oba-Shinjo SM; Ramalho LNZ; Tone LG; Valera ET
    Childs Nerv Syst; 2019 Apr; 35(4):689-694. PubMed ID: 30631904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
    Witt DA; Donson AM; Amani V; Moreira DC; Sanford B; Hoffman LM; Handler MH; Levy JMM; Jones KL; Nellan A; Foreman NK; Griesinger AM
    Pediatr Blood Cancer; 2018 May; 65(5):e26960. PubMed ID: 29350470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
    Nobusawa S; Hirato J; Yokoo H
    Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
    Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J
    J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L1CAM Immunopositivity in Anaplastic Supratentorial Ependymomas: Correlation With Clinical and Histological Parameters.
    Chavali P; Rao S; Palavalasa S; Bevinahalli N; Muthane YTC; Sadashiva N; Santosh V
    Int J Surg Pathol; 2019 May; 27(3):251-258. PubMed ID: 30251576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
    Mack SC; Pajtler KW; Chavez L; Okonechnikov K; Bertrand KC; Wang X; Erkek S; Federation A; Song A; Lee C; Wang X; McDonald L; Morrow JJ; Saiakhova A; Sin-Chan P; Wu Q; Michaelraj KA; Miller TE; Hubert CG; Ryzhova M; Garzia L; Donovan L; Dombrowski S; Factor DC; Luu B; Valentim CLL; Gimple RC; Morton A; Kim L; Prager BC; Lee JJY; Wu X; Zuccaro J; Thompson Y; Holgado BL; Reimand J; Ke SQ; Tropper A; Lai S; Vijayarajah S; Doan S; Mahadev V; Miñan AF; Gröbner SN; Lienhard M; Zapatka M; Huang Z; Aldape KD; Carcaboso AM; Houghton PJ; Keir ST; Milde T; Witt H; Li Y; Li CJ; Bian XW; Jones DTW; Scott I; Singh SK; Huang A; Dirks PB; Bouffet E; Bradner JE; Ramaswamy V; Jabado N; Rutka JT; Northcott PA; Lupien M; Lichter P; Korshunov A; Scacheri PC; Pfister SM; Kool M; Taylor MD; Rich JN
    Nature; 2018 Jan; 553(7686):101-105. PubMed ID: 29258295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods.
    de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET
    J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.
    Tzaridis T; Milde T; Pajtler KW; Bender S; Jones DT; Müller S; Wittmann A; Schlotter M; Kulozik AE; Lichter P; Peter Collins V; Witt O; Kool M; Korshunov A; Pfister SM; Witt H
    Oncotarget; 2016 Sep; 7(38):61860-61873. PubMed ID: 27556362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C11orf95-RELA, YAP1-MAMLD1, and YAP1-FAM118B Fusion Negative Anaplastic Ependymoma with Lipogenic Differentiation.
    Jha S; Mulgulwar PB; Sharma MC; Purkait S; Pattnaik A; Sable MN
    Neurol India; 2023; 71(5):1011-1014. PubMed ID: 37929446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.